Geron (GERN) Net Income towards Common Stockholders (2010 - 2026)

Geron's (GERN) quarterly Net Income towards Common Stockholders came in at -$3.6 million in Q1 2026, up 81.94% year-on-year from -$2.0 million in Q1 2025, and up 87.61% quarter-over-quarter from -$28.8 million in Q4 2025.

Geron (GERN) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends

Geron has disclosed Net Income towards Common Stockholders across 17 years of filings, most recently posting -$3.6 million for Q1 2026.

  • Net Income towards Common Stockholders for Q1 2026 came in at -$3.6 million, up 81.94% year-over-year; the trailing twelve-month figure through Mar 2026 was -$66.9 million (up 51.16% YoY), and the FY2025 annual result was -$83.1 million, up 51.85% from the prior year.
  • Net Income towards Common Stockholders came in at -$3.6 million for Q1 2026 at Geron, up from -$28.8 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of -$3.6 million in Q1 2026 to a low of -$67.3 million in Q2 2024.
  • The 5-year median for Net Income towards Common Stockholders is -$30.0 million (2022), against an average of -$34.5 million.
  • Across the five-year window, Net Income towards Common Stockholders tumbled 68.39% in 2023 and jumped 81.94% in 2026, its largest moves.
  • Geron's Net Income towards Common Stockholders stood at -$42.7 million in 2022, then retreated by 21.75% to -$52.0 million in 2023, then jumped by 54.63% to -$23.6 million in 2024, then declined by 22.02% to -$28.8 million in 2025, then jumped by 87.61% to -$3.6 million in 2026.
  • The last three Net Income towards Common Stockholders figures came in at -$3.6 million (Q1 2026), -$28.8 million (Q4 2025), and -$18.3 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Alterity Therapeutics 762,369.55 Bn 762,369.51 Bn - -
2 Belite Bio 55,096.00 Bn 55,096.00 Bn - -26.94 Mn
3 Quantum Biopharma 17,755.80 Bn 17,755.79 Bn - -13.56 Mn
4 Legend Biotech 3,486.00 Bn 3,485.71 Bn 242.10 Mn 2.50 Mn
5 Akari Therapeutics 1,737.42 Bn 1,737.41 Bn - -14.46 Mn
6 Evaxion A 1,551.28 Bn 1,551.26 Bn - -3.63 Mn
7 Psyence Biomedical 227.32 Bn 227.31 Bn - -1.50 Mn
8 Vertex Pharmaceuticals 110.84 Bn 103.59 Bn 2.59 Bn 1.03 Bn
9 Abivax 91.71 Bn 91.71 Bn - -56.48 Mn
10 Geron 729,618.77 729,618.77 - -3.57 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -3.57 Mn
Dec 31, 2025 -28.79 Mn
Sep 30, 2025 -18.27 Mn
Jun 30, 2025 -16.31 Mn
Mar 31, 2025 -19.75 Mn
Dec 31, 2024 -23.60 Mn
Sep 30, 2024 -26.38 Mn
Jun 30, 2024 -67.32 Mn
Mar 31, 2024 -55.33 Mn
Dec 31, 2023 -52.01 Mn
Sep 30, 2023 -44.71 Mn
Jun 30, 2023 -49.22 Mn
Mar 31, 2023 -38.16 Mn
Dec 31, 2022 -42.72 Mn
Sep 30, 2022 -40.91 Mn
Jun 30, 2022 -29.23 Mn
Mar 31, 2022 -30.04 Mn
Dec 31, 2021 -32.01 Mn
Sep 30, 2021 -26.62 Mn
Jun 30, 2021 -29.56 Mn